Immune Thrombocytopenia Market Report 2025

The immune thrombocytopenia market size has grown strongly in recent years. It will grow from $3.43 billion in 2024 to $3.64 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth during the historic period can be attributed to factors such as the rising prevalence of autoimmune disorders, an increase in the incidence of chronic liver diseases, greater access to healthcare services, expansion of healthcare infrastructure, and growing government support.

The immune thrombocytopenia market size is expected to see strong growth in the next few years. It will grow to $4.58 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth during the forecast period can be attributed to factors such as the increasing prevalence of thrombocytopenia, rising healthcare spending, the expansion of available therapies, a growing prevalence of blood disorders, and an aging population. Key trends in the forecast period include advancements in diagnostic technologies, the integration of digital health solutions, a shift toward combination therapies, the adoption of telemedicine, and the incorporation of artificial intelligence in diagnostics.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the immune thrombocytopenia market in the future. Autoimmune diseases occur when the immune system mistakenly attacks the body’s healthy cells and tissues, treating them as foreign invaders. This abnormal immune response causes inflammation and damage to various organs and systems. The rise in autoimmune diseases can be attributed to factors such as genetic predispositions, environmental influences, lifestyle changes, and greater awareness leading to improved diagnosis. Autoimmune diseases can cause immune thrombocytopenia by prompting the immune system to attack and destroy platelets or interfere with their production in the bone marrow. For example, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a prevalence rate of 8.61%. Therefore, the increasing prevalence of autoimmune diseases is contributing to the growth of the immune thrombocytopenia market.

Companies in the immune thrombocytopenia market are focusing on advancing therapeutic options, especially in intravenous (IV) therapies, to improve treatment outcomes, reduce response times, increase patient adherence, and address unmet needs in thrombocytopenia management. IV therapy involves delivering fluids, medications, or nutrients directly into a patient’s vein through an intravenous line. For instance, in March 2024, Argenx SE, a biotechnology company based in the Netherlands, announced that the Japan Ministry of Health, Labor, and Welfare (MHLW) had approved VYVGART for intravenous administration in adults with primary immune thrombocytopenia (ITP). This approval marks a significant advancement in treatment, offering a targeted approach with rapid effects and sustained platelet response, addressing key gaps in autoimmune disease treatment.

In December 2024, Keros Therapeutics Inc., a U.S.-based biopharmaceutical company, formed a partnership with Takeda Pharmaceutical Industries Ltd. to develop and commercialize elritercept, a therapy designed to target disorders related to dysfunctional TGF-β signaling, including thrombocytopenia and other rare diseases. Takeda Pharmaceutical Industries Ltd., a Japan-based biopharmaceutical company, specializes in innovative treatments for thrombocytopenia and other rare diseases.

Major players in the immune thrombocytopenia market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Novartis AG, Amgen Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Intas Pharmaceuticals Ltd., CSL Behring, Griffols, UCB Pharma, Kyowa Kirin, Sobi (Swedish Orphan Biovitrum), 3SBio Inc., Biotest AG, Shionogi & Co. Ltd., Ligand Pharmaceuticals, Rigel Pharmaceuticals, Symphogen, Hansa Biopharma, and Argenx.

North America was the largest region in the immune thrombocytopenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the immune thrombocytopenia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Immune thrombocytopenia is a rare autoimmune bleeding disorder in which the immune system mistakenly attacks and destroys platelets, which are crucial for blood clotting. This results in a low platelet count, impairing the blood's ability to form clots. Common symptoms include easy bruising, bleeding, and a rash consisting of small red spots.

The primary types of immune thrombocytopenia are primary immune thrombocytopenia (ITP), secondary immune thrombocytopenia, and acquired immune thrombocytopenia. Primary ITP occurs when the immune system incorrectly targets and eliminates platelets in the blood. Treatment options for ITP include intravenous immunoglobulin, thrombopoietin receptor agonists, and immunosuppressive therapy, which are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The immune thrombocytopenia market research report is one of a series of new reports that provides immune thrombocytopenia market statistics, including the immune thrombocytopenia industry's global market size, regional shares, competitors with a immune thrombocytopenia market share, detailed immune thrombocytopenia market segments, market trends and opportunities, and any further data you may need to thrive in the immune thrombocytopenia industry. This immune thrombocytopenia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The immune thrombocytopenia market consists of revenues earned by entities by providing services such as blood or platelet transfusions, splenectomy, plasma exchange, monitoring, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The immune thrombocytopenia market also includes sales of pharmaceutical drugs, diagnostic kits and reagents, medical devices, platelet transfusion products, and supportive care products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.